Clinical Trial Update: Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating MB11 against Opdivo (nivolumab) in previously untreated advanced melanoma, assessing pharmacokinetics, efficacy, safety, and immunoge…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MB11
• OPDIVO (nivolumab)

Snippet

Sponsor: mAbxience Research S.L. | Conditions: Advanced (Unresectable or Metastatic) Melanoma | Phase 3 | Status: RECRUITING